LARSEN-&-TOUBRO-INFOTECH
6.2.2020 12:02:04 CET | Business Wire | Pressemeddelelse
Larsen & Toubro Infotech Ltd. (NSE: LTI, BSE: 540005), er en global virksomhed inden for teknologirådgivning og digitale løsninger, har udvidet sin aftale med OKQ8 AB Scandinavia. I løbet af de næste fem år vil denne aftale tranformere applikationer og OKQ8’s infrastruktur landskab med tjenester der omfatter Infrastruktur-as-a-Service (IaaS), Sikkerhedstjenester, Applikationsdrift, Vedligeholdelse og Udvikling, hvilket vil resultere i forbedret stabilitet, tilgængelighed og forudsigelighed af it-driften.
OKQ8, der har hovedkvarter i Stockholm, er en af Skandinaviens største brændstofvirksomheder med en omsætning på over 39 mia. SEK og tæt på 1000 stationer over hele Danmark og Sverige. LTI har været partner med OKQ8 siden 2017, og denne udvidede aftaler er et resultat af, hvad dette partnerskab har skabt gennem årene. Som en strategisk partner vil LTI udnytte sine omfattende evner indenfor analyse, automatisering og KI til at levere disse servicer til OKQ8.
Mikael Pålsson, CIO, OKQ8 , udtaler, “For at kunne betjene vores kunder bedre er det afgørende for OKQ8 at integrere vores økosystem som består af brændstofstationer, dagligvarebutikker, bilvaske, biludlejninger samt økonomi- og forsikringsservicer. Som vores strategiske partner bringer LTI den rette erfaring, teknologiske kompetence og kulturelle tilpasning der sikrer, at dette program bliver en fuldkommen succes.”
Arun Sankaranarayanan, Chief Business Officer, LTI Nordics , udtaler, “Siden begyndelsen I 1999 har OKQ8 konsekvent sat høje standarder for teknologiudnyttelse og ekspertise indenfor kundeservice. Vi er glade for at udvide vores partnerskab med OKQ8 for at designe næste generations arkitektur og opfylde virksomhedens vision for digital transformation. LTI vil udnytte sine evner indenfor eksponentielle teknologier og kundecentrisk tilgang til at hjælpe OKQ8 med at nå sine strategiske mål.”
LTI har en stærk tilstedeværelse I hele Norden og samarbejder med førende virksomheder for at hjælpe dem med at konkurrere effektivt i en verden i forandring.
Om LTI:
LTI (NSE: LTI) er en global virksomhed inden for teknologirådgivning og digitale løsninger, der hjælper over 420 klienter med at få succes i en konvergerende verden. Med operationer I 32 lande går vi den ekstra mil for vores klienter og fremskynder deres digitale transformation med LTIs Mosaic platform, som muliggør deres mobile, sociale, analytiske, IoT og cloud-baserede rejser. Vi blev grundlagt I 1997 som et datterselskab af Larsen & Toubro Limited, og vores unikke arv giver os en uovertruffen ekspertise til at løse de mest komplekse udfordringer for virksomheder på tværs af alle brancher. Hver dag giver vores team, på over 30.000 LTI-medarbejdere, vores kunder mulighed for at forbedre effektiviteten af deres forretnings- og teknologidrift samt levere værdi til deres kunder, medarbejdere og aktionærer. Læs mere på http://www.Lntinfotech.com eller følg os på @LTI_Global
Om OKQ8 AB :
OKQ8 Scandinavia: Den foretrukne mulighed for bæredygtig bevægelse
OKQ8 Scandinavia har operationer I Sverige og Danmark og er en af Skandinaviens største brændstofvirksomheder. Vi er en organisation med omkring 5000 ansatte som er engagerede, kundeorienterede og har fokus på bæredygtighed. Vi arbejder aktivt på at drive udviklingen af mere klima- og miljøvenlige brændstoffer og produkter fremad, på at reducere ulighed og på at bidrage til bæredygtige byer og samfund. Med omkring 1000 servicestationer, vores egen bank og et af markedets stærkeste virksomhedstilbud ønsker vi at være den foretrukne mulighed for bæredygtig forretning – både nu og i fremtiden. Læs mere på www.okq8.se
Forbind til LTI:
Se kildeudgaven på businesswire.com: https://www.businesswire.com/news/home/20200206005412/da/
Link:
Information om Business Wire
Følg pressemeddelelser fra Business Wire
Skriv dig op her, og modtag pressemeddelelser på e-mail. Indtast din e-mail, klik på abonner, og følg instruktionerne i den udsendte e-mail.
Flere pressemeddelelser fra Business Wire
Incyte Announces New Positive 54-Week Late-Breaking Data for Povorcitinib in Hidradenitis Suppurativa at the 2026 American Academy of Dermatology (AAD) Annual Meeting28.3.2026 20:00:00 CET | Press release
Phase 3 data from the STOP-HS program demonstrate povorcitinib’s substantial and durable clinical efficacy through Week 54 in patients with moderate to severe hidradenitis suppurativa (HS). Through Week 54, clinically meaningful and durable responses were observed across all groups in both STOP-HS1 and STOP-HS2, with up to 71.4% of patients achieving HiSCR50. Improvements in clinical responses across high stringent thresholds were observed, with up to 57% of participants achieving HiSCR75 and up to 29% of participants achieving HiSCR100. Povorcitinib treatment led to consistent reductions across key inflammatory lesion types, with full resolution (ANdT=0) achieved in up to 20% of patients. Additionally, clinically meaningful improvements in quality-of-life measures, including skin pain and fatigue, were observed at Week 54. The overall safety profile of povorcitinib through 54 weeks is consistent with previously reported data, and both doses were well tolerated. Incyte (Nasdaq:INCY) to
Takeda’s Zasocitinib Delivered Rapid and Durable Skin Clearance in a Convenient Once-Daily Pill, Affirming Promise to Reshape Psoriasis Care28.3.2026 20:00:00 CET | Press release
About 70% of patients treated with zasocitinib achieved clear or almost clear skin (sPGA 0/1) at week 16 in Phase 3 plaque psoriasis studies A significantly greater PASI 75 response rate versus placebo was observed as early as week 4 Safety profile consistent with Phase 2b studies with no new safety signals identified Takeda(TSE:4502/NYSE:TAK)today announced new data from the two pivotal Phase 3studies of zasocitinib (TAK-279), a next-generation, highly selective oral tyrosine kinase 2 (TYK2) inhibitor, in adults with moderate-to-severe plaque psoriasis (PsO).1 Presented as a late-breaking abstract at the 2026 American Academy of Dermatology (AAD) Annual Meeting, these data show that convenient once-daily oral zasocitinib demonstrated rapid and durable skin clearance with a safety profile consistent with Phase 2b studies.1,2 “Our goal in psoriasis treatment is clear or almost clear skin, and previously this has been achieved primarily with injectable therapies,” said Melinda Gooderham,
AAD 2026: Late-Breaking Nemolizumab Data Demonstrate Clinically Meaningful Benefits for Children Aged 2 to 11 With Moderate-to-Severe Atopic Dermatitis28.3.2026 16:00:00 CET | Press release
Pharmacokinetics, safety and efficacy clinical study data show that nemolizumab achieved clinically meaningful reductions in skin lesions and itch through Week 16, which were sustained up to a year in children aged 2 to 11 with moderate-to-severe atopic dermatitis1 These findings reinforce the previously established safety and efficacy of nemolizumab in adults and adolescents with moderate-to-severe atopic dermatitis, for which it is approved by multiple global regulatory authorities2,3 Up to 25% of children are affected by atopic dermatitis, and currently there are limited approved treatment options for children living with moderate-to-severe atopic dermatitis4,5 Galderma (SIX: GALD) today announced new phase II data showing that nemolizumab was well tolerated and effective in children (aged 2 to 11 years) with moderate-to-severe atopic dermatitis, with a clinically meaningful and sustained reduction in skin lesions and itch for up to a year.1 Results will be presented in a late-break
Angelalign Technology (6699.HK)Releases 2025 Results: Passion for Clinical Excellence Drives Worldwide Growth27.3.2026 20:56:00 CET | Press release
Angelalign Technology Inc. (6699.HK) (“Angel” or the “Company”) released its financial results for fiscal year 2025. During the reporting period, the Company continued to do well in both the global and China markets. Total case volume was 532,400, which increased 48.1%, revenue was USD 370.3 million, which increased 37.8%, and adjusted net profit was USD 43.8 million, which increased 63.0%. The results were driven by Angel’s passion for clinical excellence and its open and inclusive culture that empowers talented people to work together to meet customer needs, the Company said. Fox Hu, CEO of Angel, stated: “The clear aligner industry is complex and multidisciplinary. It requires top-tier technical and operational talent along with seamless collaboration among professionals from diverse geographies. Angel’s open and inclusive culture attracts professionals who share a passion for clinical excellence and a dedication to bringing outstanding products and services to customers. This melti
Axway Positioned as a Leader in the IDC MarketScape: Worldwide API Management 2026 Vendor Assessment27.3.2026 18:46:00 CET | Press release
Axway, a 74Software company (Euronext: 74SW) and global leader in federated API management and enterprise integration, has been named a Leader in the IDC MarketScape: Worldwide API Management 2026 Vendor Assessment.1 Axway Amplify securely connects, orchestrates, and automates data integration. Organizations in financial services, manufacturing, healthcare, and other industries rely on Amplify to modernize integrations and confidently unlock data to deliver superior digital services faster. The report notes: “The platform benefits from Axway’s long-standing experience in B2B integration, secure file transfer, and legacy connectivity, providing differentiated capabilities for organizations that need to expose and control APIs around core systems that are not cloud-native.”1 This multi-pattern expertise in security, integration, and federated governance — built during the early phases of the API-driven digital transformation — becomes especially critical as enterprises seek to govern dat
I vores nyhedsrum kan du læse alle vores pressemeddelelser, tilgå materiale i form af billeder og dokumenter samt finde vores kontaktoplysninger.
Besøg vores nyhedsrum